Fate Therapeutics Inc (FATE)

[jondoeuk]

CT041, an auto anti-CLDN18.2 CAR-T has shown promising activity, with an ORR (across three different trials) of ~60%, in patients with gastric, gastro-esophageal junction and pancreatic cancers. However, mPFS, mDOR and mOS need improving, which is where that could come in. I know they already add nab-paclitaxel as part of the preconditioning regimen.

Also, the same company showed a synergistic effect of CAR-T with tyrosine kinase inhibitors. In the paper, sorafenib augmented effects by promoting IL-12 secretion in TAMs, as well as cancer cell apoptosis https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(19)30186-8

In addition, there is this case report https://www.frontiersin.org/articles/10.3389/fimmu.2022.963031/full